$0.00 down $0.31, 99.68% at close Oct 16
Last close · Previous close $0.31
$0.00down $0.36, 99.72%Past month
Use the left and right arrow keys to move along the chart.
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
The average daily shares traded over the last 21 trading sessions, about one calendar month.
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ANEB beat the S&P 500 in 1 of 6 periods.
| Period | ANEB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ANEB: down 99.7% S&P 500: up 1.5% | ANEB trailed the S&P 500 by 101.2 percentage points Trailed |
| 3M | ANEB: up 150.0% S&P 500: up 1.9% | ANEB beat the S&P 500 by 148.1 percentage points Beat |
| YTD | ANEB: down 99.9% S&P 500: up 12.8% | ANEB trailed the S&P 500 by 112.7 percentage points Trailed |
| 1Y | ANEB: down 100.0% S&P 500: up 16.8% | ANEB trailed the S&P 500 by 116.8 percentage points Trailed |
| Long term | ||
| 3Y | ANEB: down 99.9% S&P 500: up 81.5% −91.6% vs +22.0% a year | ANEB trailed the S&P 500 by 181.4 percentage points Trailed |
| 5Y | ANEB: down 100.0% S&P 500: up 83.1% −83.1% vs +12.9% a year | ANEB trailed the S&P 500 by 183.1 percentage points Trailed |
$10,000 invested in ANEB 5 years ago (Oct 15, 2021) would be worth about $1 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $18,305.
ANEB beat the S&P 500 in 1 of 6 periods.
| Period | ANEB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ANEB: down 99.7% S&P 500: up 1.2% | ANEB trailed the S&P 500 by 100.9 percentage points Trailed |
| 3M | ANEB: up 150.0% S&P 500: up 1.7% | ANEB beat the S&P 500 by 148.3 percentage points Beat |
| YTD | ANEB: down 99.9% S&P 500: up 11.9% | ANEB trailed the S&P 500 by 111.8 percentage points Trailed |
| 1Y | ANEB: down 100.0% S&P 500: up 15.5% | ANEB trailed the S&P 500 by 115.5 percentage points Trailed |
| Long term | ||
| 3Y | ANEB: down 99.9% S&P 500: up 75.0% −91.6% vs +20.5% a year | ANEB trailed the S&P 500 by 174.9 percentage points Trailed |
| 5Y | ANEB: down 100.0% S&P 500: up 71.2% −83.1% vs +11.4% a year | ANEB trailed the S&P 500 by 171.2 percentage points Trailed |
$10,000 invested in ANEB 5 years ago (Oct 15, 2021) would be worth about $1 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $17,118.
$8.95
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since May 7, 2021.
ANEB hasn’t split since its price history begins in 2021.
The Oct 16 close compared with the last 12 months of reported results (the four quarters to Dec 31, 2025). Tap a metric to see how it’s calculated.
n/mDiluted EPS of −$0.19 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Price relative to accounting equity (book value) per share on the Dec 31, 2025 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratioFree cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flowWhat it would cost to buy the whole business: the market cap at the Oct 16 close, plus debt, minus cash and short-term investments from the Dec 31, 2025 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explainedBuild your own ANEB DCF in Excel. Value Anebulo Pharmaceuticals with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Dec 31, 2025. “Last 12 months” means the four quarters from Jan 1, 2025 to Dec 31, 2025, and balance-sheet figures are as of Dec 31, 2025.
Last 12 months, with the change from the 12 months before
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Mar 31, 2024) | $0.00 | −$1.65M | −$0.06 |
| Q4 FY24 (Jun 30, 2024) | $0.00 | −$1.35M | −$0.05 |
| Q1 FY25 (Sep 30, 2024) | $0.00 | −$2.20M | −$0.08 |
| Q2 FY25 (Dec 31, 2024) | $0.00 | −$2.46M | −$0.09 |
| Q3 FY25 (Mar 31, 2025) | $0.00 | −$1.68M | −$0.04 |
| Q4 FY25 (Jun 30, 2025) | $0.00 | −$2.14M | −$0.05 |
| Q1 FY26 (Sep 30, 2025) | $0.00 | −$2.16M | −$0.05 |
| Q2 FY26 (Dec 31, 2025) | $0.00 | −$2.00M | −$0.05 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Jun 30, 2021) | $0.00 | −$30.25M | −$2.83 |
| FY22 (Jun 30, 2022) | $0.00 | −$6.83M | −$0.29 |
| FY23 (Jun 30, 2023) | $0.00 | −$11.73M | −$0.47 |
| FY24 (Jun 30, 2024) | $0.00 | −$8.20M | −$0.32 |
| FY25 (Jun 30, 2025) | $0.00 | −$8.48M | −$0.25 |
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flowCash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
Cash plus short- and long-term marketable securities on the Dec 31, 2025 balance sheet.
Current assets divided by current liabilities on the Dec 31, 2025 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratioTotal debt divided by shareholders’ equity on the Dec 31, 2025 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratioOver the last 12 months, Anebulo Pharmaceuticals lost money: its net loss was 74.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equityOver the last 12 months, Anebulo Pharmaceuticals’s net loss was 69.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assetsAnebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel solutions for people suffering from cannabis-induced toxicity. Its lead product candidate, selonabant, has completed a Phase 2 clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication in healthy adults challenged with oral THC. Rather than proceeding directly with Phase 3 studies of oral selonabant in adults with ACI, the Company is prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity, which it believes offers the potential for a faster timeline to approval relative to the adult oral product. Anebulo is currently scaling up the intravenous formulation for initial clinical safety studies. Selonabant is a competitive antagonist at the human CB1 receptor.
Top story
Over the last 7 days, the United States market has dropped 1.4%, but it has risen by 16% over the past year, with earnings forecasted to grow annually by 18%. In such a dynamic market, identifying stocks that combine affordability with growth potential is…
Headlines from Tiingo News. Repeats and auto-generated sites are filtered out; links open the publisher’s site.
Prices are from the last refresh. Open any stock for its live dashboard.
Anebulo Pharmaceuticals (ANEB) traded at $0.00 at the close on , down $0.31 (99.68%) from the previous close of $0.31. Over the past 52 weeks it has traded between $0.00 and $2.85.
With dividends reinvested, $1,000 invested in ANEB on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested one year ago. Past performance doesn’t predict future returns.
Anebulo Pharmaceuticals’s market capitalization is about $41.1 thousand. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.00 (how market cap works). Anebulo Pharmaceuticals reported 41.08M shares outstanding at the end of its latest quarter ().
ANEB’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.19).
ANEB’s diluted earnings per share were −$0.19 over the four quarters to , compared with −$0.28 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.05 per share, against −$0.09 a year earlier (how EPS works).
Anebulo Pharmaceuticals hasn’t paid a dividend in the last twelve months.
Over the past 52 weeks ANEB has traded as low as $0.00 and as high as $2.85. At $0.00 at the close on , it is 100.0% below that high and 150.0% above the low.
ANEB’s highest closing price was $8.95 on , adjusted for stock splits. At $0.00 at the close on , it is 100.0% below that record.
No. ANEB hasn’t split since its price history begins in 2021.
Including dividends and measured to the close on , ANEB has returned −99.9% so far this year and −100.0% over the past year, and −100.0% over five years (−83.1% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
Anebulo Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in Texas, USA.
Anebulo Pharmaceuticals trades on the PINK under the ticker symbol ANEB. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.
